From: FiercePharma By: Angus Liu Tuesday, AbbVie said the FDA has green-lighted its Qulipta, or atogepant, for prevention of episodic migraine.
One month post launch, Spherix data indicates that Aduhelm (aducanumab-avwa) awareness easily outpaces other key performance indicators, including degree of
Neurologists in Canada are receptive to having a fourth S1P receptor modulator option in Janssen’s Ponvory, although increasing the clinical
According to new research from Spherix Global Insights, the FDA approval of Farxiga is likely to ignite a shift towards
According to Spherix Global Insights, rheumatologists and nephrologists are excited about new treatment options in addition to a multitude of
Infliximab and adalimumab biosimilars continue to increase their presence in ulcerative colitis and Crohn’s disease therapy switching, while Entyvio SC
According to Spherix Global Insights, nephrologists anxiously await pipeline products such as Retrophin’s sparsentan, Aurinia’s voclosporin, Reata’s bardoxolone methyl, and
According to Spherix Global Insights’ latest quarterly survey of 101 US nephrologists, despite anticipated increases in use, over one-third of
The newest market entrant and possibly next autoimmune blockbuster has had an impressive launch so far, according to Spherix Global
Looking to the future, the approval of the first dual-therapy migraine label would make Nurtec a substantial competitive threat on
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked
With a plethora of agents in development, manufacturers who already have one leg in the dermatology biologic/small molecule space, such
